Document:

EXHIBIT 10.2

                                                               Annual Grant Form

                            STOCK OPTION CERTIFICATE
                             for Stock Option Grant
                              Under the Viacom Inc.
                  2000 Stock Option Plan for Outside Directors
                (As Amended and Restated Through March 10, 2004)

         This STOCK OPTION CERTIFICATE sets forth the terms of the [Insert Date
of Grant] grant of a stock option to [Insert Name of Director] (the "Director")
by Viacom Inc., a Delaware corporation (the "Company"), under the Viacom Inc.
2000 Stock Option Plan for Outside Directors, as amended and restated through
March 10, 2004 (the "Plan").

                                   WITNESSETH:

         WHEREAS, the Company has adopted the Plan for the purpose of obtaining
and retaining the services of qualified persons who are not employees of the
Company or National Amusements, Inc. or their subsidiaries to serve as directors
and to induce them to make a maximum contribution to the success of the Company
and its subsidiaries; and

         WHEREAS, the Plan provides for the automatic grant on an annual basis
on each January 31st of a non-qualified option for 4,000 shares of the Company's
Class B Common Stock, par value $0.01 per share (the "Class B Common Stock"), to
each person (i) who is a member of the Board on the date of grant, and (ii) who
is not an employee of the Company or National Amusements, Inc. or any of their
subsidiaries or a member of the immediate family of a member of the Board who is
an employee of any of such companies (an "Outside Director"); and

         WHEREAS, the Director is an Outside Director eligible for an automatic
grant under the terms and conditions of the Plan.

                             TERMS OF STOCK OPTIONS

         1. Grant of Stock Option. Subject to the terms and conditions contained
in this Certificate and in the Plan, the terms of which are incorporated herein
by reference, the Company hereby grants to the Director, effective as of [Insert
Date of Grant] (the "Date of Grant"), the option (the "Stock Option") for 4,000
shares of Class B Common Stock at an exercise price of $[Insert Exercise Price]
for each share (the "Exercise Price"), which is equal to the Fair Market Value
(as defined below) of a share of Class B Common Stock on the Date of Grant. The
"Fair Market Value" of a share of Class B Common Stock on a given date shall be
the closing price on such date on the New York Stock Exchange or other principal
stock exchange on which the Class B Common Stock is then listed, as reported by
the The Wall Street Journal (Northeast edition) as the 4:00 p.m. (New York time)
closing price or as reported by any other authoritative source selected by the
Company. The Stock Option is not intended to be, or qualify as, an "Incentive
Stock Option" within the meaning of Section 422 of the Internal Revenue Code of
1986, as amended.

<PAGE>

         2. Vesting; Exercise. The Stock Option shall vest in three equal
installments, on the first, second and third anniversaries of the Date of Grant.
The Stock Option may be exercised until the tenth anniversary of the Date of
Grant (the "Expiration Date"). In the event that (A) the services of the
Director as a director of the Company terminate for any reason other than for
death or permanent disability, the Director may exercise the Stock Option, to
the extent it was vested on such termination date, until the earlier of the
first anniversary of such termination date or the Expiration Date, (B) the
Director dies while serving as a director, it may be exercised, to the extent it
was vested on the date of death, by the person who acquired the right to
exercise the Stock Option by will or the laws of descent and distribution until
the earlier of the first anniversary of the date of death or the Expiration
Date, and (C) the services of the Director as a director of the Company
terminate by reason of permanent disability, the Director may exercise the Stock
Option, to the extent it was vested when his or her services terminated, until
the earlier of the first anniversary of such termination or the Expiration Date.
Upon the occurrence of an event described in clauses (A), (B) or (C), if the
Stock Option was not fully vested on the date of such event, the portion that
was not vested will be relinquished.

         3. Method of Exercise. The Director may exercise the Stock Option, to
the extent vested, at one time or in part (provided that the Stock Option must
be exercised in increments of 500 shares) by written notice to the
Administrator, Long-Term Incentive Plans, Viacom Inc. 1515 Broadway, New York,
New York 10036, or to such agent(s) for the Company ("Agent") as the Company may
from time to time specify, in such manner and at such address as may be
specified from time to time by the Company. If exercised in part, the Stock
Option shall remain exercisable as to any remaining underlying shares for the
remainder of the period set forth in paragraph 2. Such notice shall (i) state
the number of shares to be purchased pursuant to the Stock Option, and (ii) be
signed (or otherwise authorized in a manner acceptable to the Company) by the
person or persons so exercising the Stock Option and, in the event the Stock
Option is being exercised by any person or persons other than the Director,
accompanied by proof satisfactory to the Company's counsel of the right of such
person or persons to exercise the Stock Option. Full payment of the aggregate
Exercise Price, which shall be determined by multiplying the number of shares of
Class B Common Stock to be acquired upon exercise of the Stock Option by the
Exercise Price, shall be made on or before the settlement date for such shares
of Class B Common Stock. Such Exercise Price shall be paid in cash (e.g.
personal bank check, certified check or official bank check). Upon satisfaction
of the foregoing conditions, the Company shall deliver (or cause to be
delivered) a certificate or certificates for the shares of Class B Common Stock
issued pursuant to the exercise of the Stock Option to the Director. Information
concerning any Agent and its address may by obtained by contacting the
Administrator, Long-Term Incentive Plans.

         4. Effect of Certain Corporate Changes. In the event of any merger,
consolidation, stock split, dividend, distribution, combination,
recapitalization or reclassification that changes the character or amount of the
Class B Common Stock or any other changes in the corporate structure, equity
securities or capital structure of the Company, the Board shall make such
proportionate adjustments to the number and kind of securities subject to the
Stock Option and the exercise price of the Stock Option, as it deems
appropriate. The Board may, in its sole discretion, also make such other
adjustments as it deems appropriate in order to preserve, but not increase, the
benefits or potential benefits intended to be made available hereunder upon the
occurrence of any of the foregoing events. The Board's determination as to what,
if any, adjustments shall be made shall be final and binding.

<PAGE>

         5. Miscellaneous.

           (a) Restriction on Transfer. The rights of the Director with
respect to the Stock Option shall not be transferable by the Director, except
(i) by will or the laws of descent and distribution, (ii) upon prior notice to
the Company, for transfers to members of the Director's immediate family or
trusts whose beneficiaries are members of the Director's immediate family,
provided, however, that such transfer is being made for estate and/or tax
planning purposes without consideration being received therefor, (iii) upon
prior notice to the Company, for transfers to a former spouse incident to a
divorce or (iv) for such other transfers as the Board may approve, subject to
any conditions and limitations that it may, in its sole discretion, impose.

         (b) Stockholder Rights. This grant of the Stock Option does
not entitle the Director to any rights of a holder of shares of Class B Common
Stock, except upon the delivery of share certificates to the Director upon
exercise of the Stock Option.

         (c) No Right to Reelection. Nothing in this Certificate shall
be deemed to create any obligation on the part of the Board to nominate any of
its members for reelection by the Company's stockholders, nor confer upon the
Director the right to remain a member of the Board for any period of time, or at
any particular rate of compensation.

         (d) Exercise Periods Following Termination of Services. For
the purposes of determining the dates on which the Stock Option may be exercised
following a termination of services or the death or disability of the Director,
the day following the date of such event shall be the first day of the exercise
period and the Stock Option may be exercised up to and including the last
business day falling within the exercise period.

         6. Governing Law. This Certificate and all rights hereunder shall be
construed in accordance with and governed by the laws of the State of Delaware.

                                            VIACOM INC.

                                            By: _________________________
                                                Name:  William A. Roskin
                                                Title: Executive Vice President,
                                                       Human Resources and
                                                       Administration<PAGE>
                                                                    Exhibit 10.1

                              CONSULTING AGREEMENT

            THIS CONSULTING AGREEMENT ("Agreement") dated as of October 1, 1996,
is made and entered into by and between ONCOGENE SCIENCE, INC., a Delaware
corporation (the "Company"), and EDWIN A. GEE, PH.D. (the "Consultant").

                              W I T N E S S E T H:

            WHEREAS, the Company, a leader in the innovation of drug discovery
technologies, combines genetically engineered live-cell assays with high
throughput screening to discover novel, small molecule pharmaceuticals;

            WHEREAS, the Consultant has served as a director of the Company
since 1985 and as Chairman of the Board of the Company since 1987;

            WHEREAS, prior to the Consultant's service as a director of the
Company, the Consultant served in various senior executive positions, including
President, Chairman of the Board, and Chief Executive Officer of International
Paper Company, and Senior Vice President, member of the Executive Committee and
a director of E.I. du Pont de Nemours and Company;

            WHEREAS, the Consultant has also served as an outside director of a
number of corporations in a wide range of businesses;

            WHEREAS, the Company has derived great value from the Consultant's
service as a director and Chairman of the Board of the Company and as a
consultant to the Company, and the Company desires to continue to obtain
consulting services from the Consultant in furtherance of the Company's
interests; and

            WHEREAS, the Consultant desires to continue to provide consulting
services to the Company on the terms and conditions hereinafter set forth;

            NOW, THEREFORE, in consideration of the foregoing and the mutual
promises hereinafter set forth, the parties, intending to be legally bound,
hereby agree as follows:

      1. ENGAGEMENT. The Company hereby retains the Consultant and the
Consultant hereby agrees to provide consulting services to the Company upon the
terms and conditions set forth herein.

      2. COMPENSATION.

            (a) The Company shall pay to the Consultant a fee at the rate of
$50,000 per year, payable in monthly installments on the first day of each month
commencing October 1, 1996. As of October 1, 1997, the amount payable to the
Consultant shall be adjusted to reflect changes in

                                       5
<PAGE>
the cost of living, by multiplying the monthly sum then payable by a fraction,
the numerator of which shall be the Consumer Price Index--All Items for the
United States, as published by the U.S. Department of Labor, or any comparable
successor index (the "CPI"), as of September 30, 1997, and the denominator of
which shall be the CPI as of September 30, 1996. Similar adjustments shall be
made each October 1 during the term of this Agreement.

            (b) It is expressly understood and agreed that payment of the fee
provided in paragraph (a) shall continue in the event of any temporary or
permanent disability of the Consultant which shall prevent the Consultant from
providing consulting services hereunder.

            (c) Any expenses incurred by the Consultant in connection with this
Agreement will be reimbursed by the Company pursuant to its regular established
procedures for this purpose.

      3. CONSULTING SERVICES.

            (a) During the term of this Agreement, the Consultant shall perform
such consulting services within his competence and expertise. Such services
shall be provided from time to time as shall be reasonably requested by the
Company, but not in excess of an average of one day per month.

            (b) During the term of this Agreement, the Consultant shall not,
without the prior written consent of the Company, provide consulting services
for or to any other person or entity engaged in the same business as the
Company.

      4. TERM. The term of this Agreement will commence on the date of this
Agreement and shall continue for the Consultant's lifetime.

      5. CONFIDENTIAL AND PROPRIETARY INFORMATION.

            (a) All information concerning the Company (whether written or oral)
disclosed in connection with this Agreement shall be received and retained by
the Consultant as strictly confidential. Notwithstanding the foregoing, there
shall be no obligation to retain as confidential information which (i) is in the
public domain at the time of receipt or comes into the public domain without
breach of this Section; (ii) can be shown to have been known by the Consultant
prior to receipt; (iii) becomes known to the Consultant through a third source
whose own knowledge was acquired entirely independent of the Consultant; or (iv)
is approved for disclosure by the Company in writing.

            (b) All business or technical information identified by the Company
or reasonably identifiable as proprietary to the Company and which the
Consultant was put in a position to discover in the conduct of his duties
hereunder shall be and remain the exclusive property of the Company at all times
and shall be returned to the Company upon its request or upon termination of
this Agreement.

            (c) The Consultant acknowledges that by reason of the uniqueness of
the Company's business that the covenants set forth in this Section are
reasonable and necessary for the

                                       6
<PAGE>
protection of the Company's legitimate business interests.

            (d) The Consultant hereby acknowledges that irreparable harm will
result to the Company in the event of the breach of the covenants contained in
this Section. In the event that the Consultant breaches any of the covenants
contained in this Section, the Consultant agrees that in addition to all other
remedies or damages which may be available, the Company shall be entitled to
seek and obtain both temporary and permanent restraining orders or injunctions
issued by a court in order to prevent the violation of any of the covenants made
by the Consultant pursuant to this Agreement.

            (e) The Consultant expressly acknowledges and agrees that the
provisions of this Section shall survive the termination of this Agreement.

      6. GOVERNING LAW. The validity, enforceability and interpretation of this
Agreement shall be determined in accordance with the laws of the State of New
York.

      7. RELATIONSHIP CREATED. The relationship of the Consultant and the
Company is that of independent contractors. Nothing contained in this Agreement
shall be construed to place the Company and the Consultant in a relationship as
partners, joint venturers, employer and employee or principal and agent.

      8. ASSIGNMENT. The Consultant shall not assign, convey or transfer this
Agreement or any part of his rights under this Agreement without the prior
written consent of the Company. Any such assignment, conveyance or transfer
without the Company's prior written consent shall be void.

      9. NOTICES.

            Any notice or other communication required or permitted to be given
pursuant to the provisions of this Agreement shall be deemed to have been
sufficiently given, if in writing and either delivered against receipt or sent
by registered or certified mail, with postage prepaid, addressed as indicated
and shall be deemed sent and delivered on the third day following the deposit
thereof in the United States mail:

                  If to the Company:

                        Oncogene Science, Inc.
                        106 Charles Lindbergh Blvd.
                        Uniondale, New York 11553-3649
                        Attn.:  Robert L. Van Nostrand,
                                Vice President, Finance and Administration

                  If to the Consultant:

                        Edwin A. Gee, Ph.D.
                        109 Plantation Circle
                        Ponte Vedra Beach, Florida 32082

                                       7
<PAGE>
            Either party may, by notice as aforesaid, designate a different
address or addresses for notices or other communications intended for it.

      10. PARTIES IN INTEREST. This Agreement shall be binding upon and inure to
the benefit of the parties hereto and their respective heirs, administrators,
successors and permitted assigns.

      11. MISCELLANEOUS.

            (a) This Agreement constitutes the entire understanding between the
parties with respect to the subject matter hereof and supersedes and cancels any
and all previous contracts or agreements between the parties with respect to the
subject matter hereof. It may not be altered, amended or modified except by
written instrument duly executed by the parties hereto. This Agreement shall
become binding only after the same is signed by an officer of the Company at its
general offices.

            (b) The headings contained herein are inserted for convenience only
and shall not be deemed to have any substantive meaning.

            (c) This Agreement may be executed in two or more counterparts, each
of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

            IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be executed on the day and year first above written.

                                        ONCOGENE SCIENCE, INC.

                                        By: /s/ Gary E. Frasier
                                            ------------------------------------
                                        Name: Gary E. Frasier
                                        Title: Chief Executive Officer

                                        /s/ Edwin A. Gee, Ph.D.
                                        ----------------------------------------
                                        EDWIN A. GEE, PH.D.

                                       8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00077-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00077-of-00352.parquet"}]]